However, by replacing arginine with threonine, the ECL2 of GLP-2R is no longer able to dip into the receptor core and becomes distant from the N-terminal histidine of GLP-2
Yang et al described the damaging effects of TMAO on pancreatic acinar cells
GLP-1 receptor agonist medications are FDA-approved for adults who meet one of the following criteria: a body mass index (BMI) of 30 or higher (classified as obesity), or a BMI of 27 or higher (overweight) combined with at least one weight-related health condition such as type 2 diabetes, high blood pressure, high cholesterol, sleep apnea, or cardiovascular disease
This amount is lower than the dose used in animal experiments after conversion [13,32,33]
The therapeutic implications were obvious: if you could block myostatin in a person on purpose, you might be able to rebuild muscle lost to dystrophy, aging, or as it turns out weight-loss drugs